Genome Medical and xCures have joined forces to provide patients with a new level of personalized care. Through this collaboration, Genome Medical’s genetic counselors will have access to xCures’ comprehensive care summaries for patients based on electronic medical records from across the healthcare ecosystem. This information will be used to… Read more »
Technology and Solutions to Beat Cancer
The xCures technology platform automatically creates a comprehensive outline of a cancer patient’s medical history generated from the hospitals and clinics visited. Patients get immediate access to the care summary and all of their medical data in one easy-to-access place, greatly facilitating the finding of promising treatment options.
How It Works
The xCures platform transforms complex unstructured medical data directly from the patient’s medical records into structured data suitable for analysis and review. Our A.I. engine can actively cross-reference this data against the vast digital library of oncology data to match patients with potential treatments. This empowers patients and their oncologists to make more informed and effective treatment decisions.
For Patients
For Providers
Our Platform Speaks Oncology
At the center of the xCures platform is our highly specialized Natural Language Processor (NLP) that can read, interpret, and encode raw unstructured patient data from anywhere in the United States. Our NLP speaks the language of oncology. The result is structured data in a crisp care summary for use by patients, doctors, and algorithms to find and speed up access to promising treatment options.
Our DNA Is Patient-First Precision Oncology

At Cancer Commons we’ve helped thousands of patients with one-on-one research for the best treatment options. With xCures, we can help many, many more.
Erika Vial MonteverdiFormer Executive Director, Cancer Commons
Creating Real World Evidence
The xCures platform captures Real World Evidence (RWE) from patients being treated in clinical trials, compassionate use and managed access programs, virtual and decentralized studies, investigator-initiated studies, and even N-of-1 clinical studies. The platform integrates data from all these sources, effectively creating a ‘perpetual trial’ that continuously refines treatments and improves outcomes.
This RWE gives patients and oncologists more options, and researchers more valuable data. The xCures platform accelerates clinical research by capturing regulatory-grade outcomes from real world populations – data that can be directly submitted to the FDA or to support the use of novel combination therapies.
“The program we ran on the xCures platform materially accelerated our development program of ONC201”
Wolfgang Oster MD, PhD
Founder Oncoceutics
The Team: Technology Meets Oncology
To fully integrate cancer research and care, xCures has assembled a multi-disciplinary, boundary-pushing team spanning A.I., data science, and clinical research. The team has solved three of the biggest challenges in applying A.I. to oncology:
- Medical data processing: We automated mechanisms to get a deep clinical understanding of cancer patients and structure longitudinal data without adding any additional administrative burden to the system.
- Treatment indexing: We created a living master catalog of all the potential cancer treatments, including individual interventions and combination regimens, expert-sourced medical rationales, and access pathways.
- Patient-Treatment matching: We developed a suite of tools to match patients to a shortlist of appropriate options using NLP, and rank them using Bayesian predictive models operating on real outcomes data, and expert insights mined from Virtual Tumor Boards.
Latest News
xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study
RenovoRx’s Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life. [EINPresswire] xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as… Read more »
xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study
RenovoRx’s Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life. [EINPresswire] xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as… Read more »